Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Radiation-Induced Mitotic Catastrophe Enhanced by Gold Nanoparticles: Assessment with a Specific Automated Image Processing Workflow.

Paquot H, Daouk J, Chateau A, Rétif P, Barberi-Heyob M, Pinela S.

Radiat Res. 2019 Jul;192(1):13-22. doi: 10.1667/RR14962.1. Epub 2019 Apr 25.

PMID:
31021734
2.

Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment.

Pinel S, Thomas N, Boura C, Barberi-Heyob M.

Adv Drug Deliv Rev. 2019 Jan 1;138:344-357. doi: 10.1016/j.addr.2018.10.013. Epub 2018 Nov 7. Review.

3.

AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine.

Lux F, Tran VL, Thomas E, Dufort S, Rossetti F, Martini M, Truillet C, Doussineau T, Bort G, Denat F, Boschetti F, Angelovski G, Detappe A, Crémillieux Y, Mignet N, Doan BT, Larrat B, Meriaux S, Barbier E, Roux S, Fries P, Müller A, Abadjian MC, Anderson C, Canet-Soulas E, Bouziotis P, Barberi-Heyob M, Frochot C, Verry C, Balosso J, Evans M, Sidi-Boumedine J, Janier M, Butterworth K, McMahon S, Prise K, Aloy MT, Ardail D, Rodriguez-Lafrasse C, Porcel E, Lacombe S, Berbeco R, Allouch A, Perfettini JL, Chargari C, Deutsch E, Le Duc G, Tillement O.

Br J Radiol. 2018 Sep 18:20180365. doi: 10.1259/bjr.20180365. [Epub ahead of print]

PMID:
30226413
4.

Stimulation of medulloblastoma stem cells differentiation by a peptidomimetic targeting neuropilin-1.

Gong C, Valduga J, Chateau A, Richard M, Pellegrini-Moïse N, Barberi-Heyob M, Chastagner P, Boura C.

Oncotarget. 2018 Feb 16;9(20):15312-15325. doi: 10.18632/oncotarget.24521. eCollection 2018 Mar 16.

5.

Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma.

Thomas E, Colombeau L, Gries M, Peterlini T, Mathieu C, Thomas N, Boura C, Frochot C, Vanderesse R, Lux F, Barberi-Heyob M, Tillement O.

Int J Nanomedicine. 2017 Sep 26;12:7075-7088. doi: 10.2147/IJN.S141559. eCollection 2017.

6.

Polymer-lipid-PEG hybrid nanoparticles as photosensitizer carrier for photodynamic therapy.

Pramual S, Lirdprapamongkol K, Svasti J, Bergkvist M, Jouan-Hureaux V, Arnoux P, Frochot C, Barberi-Heyob M, Niamsiri N.

J Photochem Photobiol B. 2017 Aug;173:12-22. doi: 10.1016/j.jphotobiol.2017.05.028. Epub 2017 May 22.

PMID:
28554072
7.

Proton MR Spectroscopy and Diffusion MR Imaging Monitoring to Predict Tumor Response to Interstitial Photodynamic Therapy for Glioblastoma.

Toussaint M, Pinel S, Auger F, Durieux N, Thomassin M, Thomas E, Moussaron A, Meng D, Plénat F, Amouroux M, Bastogne T, Frochot C, Tillement O, Lux F, Barberi-Heyob M.

Theranostics. 2017 Jan 5;7(2):436-451. doi: 10.7150/thno.17218. eCollection 2017.

8.

Realtime Tracking of the Photobleaching Trajectory During Photodynamic Therapy.

Tylcz JB, Bastogne T, Bourguignon A, Frochot C, Barberi-Heyob M.

IEEE Trans Biomed Eng. 2017 Aug;64(8):1742-1749. doi: 10.1109/TBME.2016.2620239. Epub 2016 Oct 21.

PMID:
28113251
9.

Monte Carlo simulations guided by imaging to predict the in vitro ranking of radiosensitizing nanoparticles.

Retif P, Reinhard A, Paquot H, Jouan-Hureaux V, Chateau A, Sancey L, Barberi-Heyob M, Pinel S, Bastogne T.

Int J Nanomedicine. 2016 Nov 18;11:6169-6179. eCollection 2016.

10.

Carbohydrate-based peptidomimetics targeting neuropilin-1: Synthesis, molecular docking study and in vitro biological activities.

Richard M, Chateau A, Jelsch C, Didierjean C, Manival X, Charron C, Maigret B, Barberi-Heyob M, Chapleur Y, Boura C, Pellegrini-Moïse N.

Bioorg Med Chem. 2016 Nov 1;24(21):5315-5325. doi: 10.1016/j.bmc.2016.08.052. Epub 2016 Aug 29.

PMID:
27622745
11.

Robustness Analysis of a Geant4-GATE Simulator for Nanoradiosensitizers Characterization.

Retif P, Bastogne T, Barberi-Heyob M.

IEEE Trans Nanobioscience. 2016 Apr;15(3):209-17. doi: 10.1109/TNB.2016.2527720. Epub 2016 Feb 11.

PMID:
26887000
12.

Molecular modelling, synthesis and biological evaluation of peptide inhibitors as anti-angiogenic agent targeting neuropilin-1 for anticancer application.

Kamarulzaman EE, Vanderesse R, Gazzali AM, Barberi-Heyob M, Boura C, Frochot C, Shawkataly O, Aubry A, Wahab HA.

J Biomol Struct Dyn. 2017 Jan;35(1):26-45. doi: 10.1080/07391102.2015.1131196. Epub 2016 May 23.

PMID:
26766582
13.

New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy.

Kamarulzaman EE, Gazzali AM, Acherar S, Frochot C, Barberi-Heyob M, Boura C, Chaimbault P, Sibille E, Wahab HA, Vanderesse R.

Int J Mol Sci. 2015 Oct 12;16(10):24059-80. doi: 10.3390/ijms161024059.

14.

Nanoparticles for Radiation Therapy Enhancement: the Key Parameters.

Retif P, Pinel S, Toussaint M, Frochot C, Chouikrat R, Bastogne T, Barberi-Heyob M.

Theranostics. 2015 Jun 11;5(9):1030-44. doi: 10.7150/thno.11642. eCollection 2015. Review.

15.

A Model-Based Pharmacokinetics Characterization Method of Engineered Nanoparticles for Pilot Studies.

Tylcz JB, Bastogne T, Benachour H, Bechet D, Bullinger E, Garnier H, Barberi-Heyob M.

IEEE Trans Nanobioscience. 2015 Jun;14(4):368-377. doi: 10.1109/TNB.2015.2418792. Epub 2015 Apr 1.

PMID:
25838525
16.

Multifunctional ultrasmall nanoplatforms for vascular-targeted interstitial photodynamic therapy of brain tumors guided by real-time MRI.

Bechet D, Auger F, Couleaud P, Marty E, Ravasi L, Durieux N, Bonnet C, Plénat F, Frochot C, Mordon S, Tillement O, Vanderesse R, Lux F, Perriat P, Guillemin F, Barberi-Heyob M.

Nanomedicine. 2015 Apr;11(3):657-70. doi: 10.1016/j.nano.2014.12.007. Epub 2015 Jan 31.

PMID:
25645959
17.

Preclinical studies of pegylated- and non-pegylated liposomal forms of doxorubicin as radiosensitizer on orthotopic high-grade glioma xenografts.

Chastagner P, Sudour H, Mriouah J, Barberi-Heyob M, Bernier-Chastagner V, Pinel S.

Pharm Res. 2015 Jan;32(1):158-66. doi: 10.1007/s11095-014-1452-x. Epub 2014 Jul 22.

PMID:
25048636
18.

The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy.

Sancey L, Lux F, Kotb S, Roux S, Dufort S, Bianchi A, Crémillieux Y, Fries P, Coll JL, Rodriguez-Lafrasse C, Janier M, Dutreix M, Barberi-Heyob M, Boschetti F, Denat F, Louis C, Porcel E, Lacombe S, Le Duc G, Deutsch E, Perfettini JL, Detappe A, Verry C, Berbeco R, Butterworth KT, McMahon SJ, Prise KM, Perriat P, Tillement O.

Br J Radiol. 2014 Sep;87(1041):20140134. doi: 10.1259/bjr.20140134. Epub 2014 Jul 3. Review.

19.

Liposome encapsulation of curcumin: physico-chemical characterizations and effects on MCF7 cancer cell proliferation.

Hasan M, Belhaj N, Benachour H, Barberi-Heyob M, Kahn CJ, Jabbari E, Linder M, Arab-Tehrany E.

Int J Pharm. 2014 Jan 30;461(1-2):519-28. doi: 10.1016/j.ijpharm.2013.12.007. Epub 2013 Dec 16.

PMID:
24355620
20.

Preparation and characterization of mTHPC-loaded solid lipid nanoparticles for photodynamic therapy.

Navarro FP, Creusat G, Frochot C, Moussaron A, Verhille M, Vanderesse R, Thomann JS, Boisseau P, Texier I, Couffin AC, Barberi-Heyob M.

J Photochem Photobiol B. 2014 Jan 5;130:161-9. doi: 10.1016/j.jphotobiol.2013.11.007. Epub 2013 Nov 21.

PMID:
24333764
21.

Bifunctional polypyridyl-Ru(II) complex grafted onto gadolinium-based nanoparticles for MR-imaging and photodynamic therapy.

Truillet C, Lux F, Moreau J, Four M, Sancey L, Chevreux S, Boeuf G, Perriat P, Frochot C, Antoine R, Dugourd P, Portefaix C, Hoeffel C, Barberi-Heyob M, Terryn C, van Gulick L, Lemercier G, Tillement O.

Dalton Trans. 2013 Sep 14;42(34):12410-20. doi: 10.1039/c3dt50946j. Epub 2013 Jul 17.

PMID:
23860731
22.

Real-time monitoring of photocytotoxicity in nanoparticles-based photodynamic therapy: a model-based approach.

Benachour H, Bastogne T, Toussaint M, Chemli Y, Sève A, Frochot C, Lux F, Tillement O, Vanderesse R, Barberi-Heyob M.

PLoS One. 2012;7(11):e48617. doi: 10.1371/journal.pone.0048617. Epub 2012 Nov 7.

23.

Systems biology approach for in vivo photodynamic therapy optimization of ruthenium-porphyrin compounds.

Pernot M, Bastogne T, Barry NP, Therrien B, Koellensperger G, Hann S, Reshetov V, Barberi-Heyob M.

J Photochem Photobiol B. 2012 Dec 5;117:80-9. doi: 10.1016/j.jphotobiol.2012.08.012. Epub 2012 Sep 28.

PMID:
23085627
24.

Multifunctional Peptide-conjugated hybrid silica nanoparticles for photodynamic therapy and MRI.

Benachour H, Sève A, Bastogne T, Frochot C, Vanderesse R, Jasniewski J, Miladi I, Billotey C, Tillement O, Lux F, Barberi-Heyob M.

Theranostics. 2012;2(9):889-904. doi: 10.7150/thno.4754. Epub 2012 Sep 29.

25.

Tumor vascular responses to antivascular and antiangiogenic strategies: looking for suitable models.

Mriouah J, Boura C, Thomassin M, Bastogne T, Dumas D, Faivre B, Barberi-Heyob M.

Trends Biotechnol. 2012 Dec;30(12):649-58. doi: 10.1016/j.tibtech.2012.08.006. Epub 2012 Sep 26. Review.

PMID:
23021636
26.

Photodynamic molecular beacons triggered by MMP-2 and MMP-9: influence of the distance between photosensitizer and quencher onto photophysical properties and enzymatic activation.

Verhille M, Benachour H, Ibrahim A, Achard M, Arnoux P, Barberi-Heyob M, André JC, Allonas X, Baros F, Vanderesse R, Frochot C.

Curr Med Chem. 2012;19(32):5580-94.

PMID:
22978328
27.

Photodynamic therapy of malignant brain tumours: a complementary approach to conventional therapies.

Bechet D, Mordon SR, Guillemin F, Barberi-Heyob MA.

Cancer Treat Rev. 2014 Mar;40(2):229-41. doi: 10.1016/j.ctrv.2012.07.004. Epub 2012 Aug 2. Review.

PMID:
22858248
28.

Non polymeric nanoparticles for photodynamic therapy applications: recent developments.

Chouikrat R, Seve A, Vanderesse R, Benachour H, Barberi-Heyob M, Richeter S, Raehm L, Durand JO, Verelst M, Frochot C.

Curr Med Chem. 2012;19(6):781-92. Review.

PMID:
22214454
29.

In vitro radiosensitizing effects of ultrasmall gadolinium based particles on tumour cells.

Mowat P, Mignot A, Rima W, Lux F, Tillement O, Roulin C, Dutreix M, Bechet D, Huger S, Humbert L, Barberi-Heyob M, Aloy MT, Armandy E, Rodriguez-Lafrasse C, Le Duc G, Roux S, Perriat P.

J Nanosci Nanotechnol. 2011 Sep;11(9):7833-9.

PMID:
22097494
30.

Functionalized silica-based nanoparticles for photodynamic therapy.

Couleaud P, Bechet D, Vanderesse R, Barberi-Heyob M, Faure AC, Roux S, Tillement O, Porhel S, Guillemin F, Frochot C.

Nanomedicine (Lond). 2011 Aug;6(6):995-1009. doi: 10.2217/nnm.11.31. Epub 2011 Jul 4.

PMID:
21726134
31.

Quantum dot-folic acid conjugates as potential photosensitizers in photodynamic therapy of cancer.

Morosini V, Bastogne T, Frochot C, Schneider R, François A, Guillemin F, Barberi-Heyob M.

Photochem Photobiol Sci. 2011 May;10(5):842-51. doi: 10.1039/c0pp00380h. Epub 2011 Apr 9.

PMID:
21479314
32.

Stability of peptides and therapeutic success in cancer.

Pernot M, Vanderesse R, Frochot C, Guillemin F, Barberi-Heyob M.

Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):793-802. doi: 10.1517/17425255.2011.574126. Epub 2011 Apr 4. Review.

PMID:
21457110
33.

Modulation of photosensitization processes for an improved targeted photodynamic therapy.

Verhille M, Couleaud P, Vanderesse R, Brault D, Barberi-Heyob M, Frochot C.

Curr Med Chem. 2010;17(32):3925-43. Review.

PMID:
20858211
34.

Photodynamic therapy targeting neuropilin-1: Interest of pseudopeptides with improved stability properties.

Thomas N, Pernot M, Vanderesse R, Becuwe P, Kamarulzaman E, Da Silva D, François A, Frochot C, Guillemin F, Barberi-Heyob M.

Biochem Pharmacol. 2010 Jul 15;80(2):226-35. doi: 10.1016/j.bcp.2010.03.036. Epub 2010 Apr 7.

PMID:
20380812
35.

Sugar-based peptidomimetics as potential inhibitors of the vascular endothelium growth factor binding to neuropilin-1.

Novoa A, Pellegrini-Moïse N, Bechet D, Barberi-Heyob M, Chapleur Y.

Bioorg Med Chem. 2010 May 1;18(9):3285-98. doi: 10.1016/j.bmc.2010.03.012. Epub 2010 Mar 12.

PMID:
20363638
36.

Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release.

Bechet D, Tirand L, Faivre B, Plénat F, Bonnet C, Bastogne T, Frochot C, Guillemin F, Barberi-Heyob M.

Pharm Res. 2010 Mar;27(3):468-79. doi: 10.1007/s11095-009-0035-8. Epub 2010 Jan 20.

PMID:
20087632
37.

Phenomenological modeling of tumor diameter growth based on a mixed effects model.

Bastogne T, Samson A, Vallois P, Wantz-Mézières S, Pinel S, Bechet D, Barberi-Heyob M.

J Theor Biol. 2010 Feb 7;262(3):544-52. doi: 10.1016/j.jtbi.2009.10.008. Epub 2009 Oct 14.

38.

Response surface methodology: an extensive potential to optimize in vivo photodynamic therapy conditions.

Tirand L, Bastogne T, Bechet D, Linder M, Thomas N, Frochot C, Guillemin F, Barberi-Heyob M.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):244-52. doi: 10.1016/j.ijrobp.2009.04.004. Epub 2009 Jul 13.

PMID:
19604651
39.

Peptide-conjugated chlorin-type photosensitizer binds neuropilin-1 in vitro and in vivo.

Thomas N, Bechet D, Becuwe P, Tirand L, Vanderesse R, Frochot C, Guillemin F, Barberi-Heyob M.

J Photochem Photobiol B. 2009 Aug 3;96(2):101-8. doi: 10.1016/j.jphotobiol.2009.04.008. Epub 2009 May 3.

PMID:
19464192
40.

Interest of liposomal doxorubicin as a radiosensitizer in malignant glioma xenografts.

Labussière M, Aarnink A, Pinel S, Taillandier L, Escanyé JM, Barberi-Heyob M, Bernier-Chastagner V, Plénat F, Chastagner P.

Anticancer Drugs. 2008 Nov;19(10):991-8. doi: 10.1097/CAD.0b013e328313e172.

PMID:
18827564
41.

Nanoparticles as vehicles for delivery of photodynamic therapy agents.

Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M.

Trends Biotechnol. 2008 Nov;26(11):612-21. doi: 10.1016/j.tibtech.2008.07.007. Epub 2008 Sep 17. Review.

PMID:
18804298
42.

Advantages and limitations of commonly used methods to assay the molecular permeability of gap junctional intercellular communication.

Abbaci M, Barberi-Heyob M, Blondel W, Guillemin F, Didelon J.

Biotechniques. 2008 Jul;45(1):33-52, 56-62. doi: 10.2144/000112810. Review.

43.

Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. synthesis and in vivo delivery studies.

Gravier J, Schneider R, Frochot C, Bastogne T, Schmitt F, Didelon J, Guillemin F, Barberi-Heyob M.

J Med Chem. 2008 Jul 10;51(13):3867-77. doi: 10.1021/jm800125a. Epub 2008 Jun 14.

PMID:
18553957
44.

Tissue distribution and pharmacokinetics of an ATWLPPR-conjugated chlorin-type photosensitizer targeting neuropilin-1 in glioma-bearing nude mice.

Thomas N, Tirand L, Chatelut E, Plénat F, Frochot C, Dodeller M, Guillemin F, Barberi-Heyob M.

Photochem Photobiol Sci. 2008 Apr;7(4):433-41. doi: 10.1039/b718259g. Epub 2008 Feb 14.

PMID:
18385885
45.

Practical identifiability of photophysical parameters in photodynamic therapy.

Dobre S, Bastogne T, Barberi-Heyob M, Richard A.

Conf Proc IEEE Eng Med Biol Soc. 2007;2007:6633-6.

PMID:
18003546
46.

Phthalocyanines covalently bound to biomolecules for a targeted photodynamic therapy.

Taquet JP, Frochot C, Manneville V, Barberi-Heyob M.

Curr Med Chem. 2007;14(15):1673-87.

PMID:
17584072
47.

Metabolic profile of a peptide-conjugated chlorin-type photosensitizer targeting neuropilin-1: an in vivo and in vitro study.

Tirand L, Thomas N, Dodeller M, Dumas D, Frochot C, Maunit B, Guillemin F, Barberi-Heyob M.

Drug Metab Dispos. 2007 May;35(5):806-13. Epub 2007 Feb 5.

PMID:
17283031
48.

Gap junctional intercellular communication capacity by gap-FRAP technique: a comparative study.

Abbaci M, Barberi-Heyob M, Stines JR, Blondel W, Dumas D, Guillemin F, Didelon J.

Biotechnol J. 2007 Jan;2(1):50-61.

PMID:
17225250
49.

Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity.

Frochot C, Di Stasio B, Vanderesse R, Belgy MJ, Dodeller M, Guillemin F, Viriot ML, Barberi-Heyob M.

Bioorg Chem. 2007 Jun;35(3):205-20. Epub 2006 Dec 9.

PMID:
17223161
50.

Recent improvements in the use of synthetic peptides for a selective photodynamic therapy.

Schneider R, Tirand L, Frochot C, Vanderesse R, Thomas N, Gravier J, Guillemin F, Barberi-Heyob M.

Anticancer Agents Med Chem. 2006 Sep;6(5):469-88. Review.

PMID:
17017856

Supplemental Content

Loading ...
Support Center